T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications

doi:10.3390/antib2030517

Open AccessThis article is

freely available
re-usable

Antibodies 2013, 2(3), 517-534; doi:10.3390/antib2030517

Review

T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications

Maya Cohen and Yoram Reiter *

Faculty of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel

* Author to whom correspondence should be addressed.

Received: 15 August 2013; in revised form: 22 August 2013 / Accepted: 22 August 2013 / Published: 17 September 2013

(This article belongs to the Special Issue Recombinant Immunotoxins)

Download PDF Full-Text [215 KB, uploaded 17 September 2013 17:25 CEST]

Abstract: Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells. Because of their unique specificity, MHC-peptide complexes are a desirable target for novel immunotherapeutic approaches. These complexes can be targeted by recombinant T-cell receptors (TCRs). However, most TCRs produced thus far have affinities which are too low for target detection under normal assay conditions, and limited stability (due to their generation in a single-chain version). Developing high-affinity soluble antibody molecules endowed with a TCR-like specificity toward tumor epitopes, termed TCR-like antibodies, addresses the low affinity of TCRs. These TCR-like antibodies are being developed as a new immunotherapeutic class for targeting tumor cells and mediating their specific killing. In addition, these antibodies are valuable research reagents enabling the study of human class I peptide-MHC ligand-presentation and TCR–peptide–MHC interactions.

Keywords: antibodies; antibody engineering; immunotoxins; MHC-peptide complex; phage display; recombinant antibodies; T-cell receptor; cancer immunotherapy

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Cohen, M.; Reiter, Y. T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications. Antibodies 2013, 2, 517-534.

AMA Style

Cohen M, Reiter Y. T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications. Antibodies. 2013; 2(3):517-534.

Chicago/Turabian Style

Cohen, Maya; Reiter, Yoram. 2013. "T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications." Antibodies 2, no. 3: 517-534.

Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert